Nevro Reports Third-Quarter 2024 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results,
Nevro Corp. Reports Strong Q3 2024 Financial Performance
Nevro Corp ( (NVRO) ) just unveiled an announcement. Nevro Corp. reported a better-than-expected worldwide revenue and adjusted EBITDA for Q3
Siebert Reports Third Quarter 2024 Financial Results
Siebert Financial Corp.(NASDAQ:SIEB) (“Siebert”), a diversified provider of financial services, today reported financial results for the third quarter ended September 30, 2024.
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financial results for the third quarter ended September 30,
Vincerx Pharma Reports Third Quarter 2024 Financial Results
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC);
Nippon Aqua Reports Mixed Financial Results for 2024
Nippon Aqua Co., Ltd. (JP:1429) has released an update. Nippon Aqua Co., Ltd. reported a slight increase in net sales for the first nine months of
HydrogenPro ASA Reports Solid Third Quarter 2024 Financial Results
HydrogenPro ASA has announced its financial results for the third quarter of 2024, showing solid progress in key projects and overall financial performance. The company reported revenues of NOK 72 million in Q3,
Where Food Comes From, Inc. Reports 2024 Third Quarter and Nine-Month Financial Results
Third Quarter Highlights – 2024 vs. 2023Verification and certification revenue up 2% to $5.5 million from $5.4 millionProduct sales up 9% to $1.3
GlobalData on MSN1d
Nevro secures CE mark for AI-based spinal cord stimulation system
US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...
Benzinga.com2d
Why Medical Device Firm Nevro Stock Is Trading Higher On Tuesday
The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised ...
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company ...
MassDevice2d
Nevro wins CE mark for HFX iQ spinal cord stim for pain relief
Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.
Nevro Shares 21% on 3Q Revenue Beat, Raised 2024 Outlook
Nevro shares surged 21% after better-than-expected revenue in its latest quarter. Shares were trading around $6.44. The stock is down 75% on the year.
Nevro Corp. (NYSE:NVRO) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.51, ...
Business Insider2d
Nevro price target raised to $6 from $5 at Baird
Baird raised the firm’s price target on Nevro (NVRO) to $6 from $5 and keeps a Neutral rating on the shares. The firm said it remains a show-me story as the business transformation remains underway.
Nevro (NVRO) Set to Announce Quarterly Earnings on Monday
Nevro (NYSE:NVRO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, ...
Becker's Spine Review2d
Nevro's spinal cord stimulator earns CE mark
Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.
Nevro: Q3 Earnings Snapshot
The Redwood City, California-based company said it had a loss of 41 cents per share. Losses, adjusted for non-recurring gains, came to 51 cents per share. The results exceeded Wall Street expectations ...
Business Insider3d
Nevro lowers 2024 revenue view to $400M-$405M from $435M-$445M
Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on NVRO: Nevro reports Q3 EPS (41c), consensus (81c) NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings? Nevro announces ...